Cargando…

Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion

Pegylated interferon α-2a (Peg-IFN-α) represents a therapeutic alternative to the prolonged use of nucleos(t)ide analog (NA) in chronic hepatitis B (CHB) infection. The mechanisms leading to a positive clinical outcome remain unclear. As immune responses are critical for virus control, we investigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruder Costa, Juliana, Dufeu-Duchesne, Tania, Leroy, Vincent, Bertucci, Inga, Bouvier-Alias, Magali, Pouget, Noelle, Brevot-Lutton, Ophelie, Bourliere, Marc, Zoulim, Fabien, Plumas, Joel, Aspord, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922676/ https://www.ncbi.nlm.nih.gov/pubmed/27348813 http://dx.doi.org/10.1371/journal.pone.0158297

Ejemplares similares

Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection
por: Aspord, Caroline, et al.
Publicado: (2016)

Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Prediction for HBsAg seroconversion in children with chronic hepatitis B
por: Zhong, Yan-Wei, et al.
Publicado: (2021)

Comparison of Serum HBsAg Quantitation by Four Immunoassays, and Relationships of HBsAg Level with HBV Replication and HBV Genotypes
por: Tuaillon, Edouard, et al.
Publicado: (2012)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals
por: Matthews, Gail V., et al.
Publicado: (2013)

Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg(+) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants?
por: Chen, Tianyan, et al.
Publicado: (2013)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
por: Jiang, Shaowen, et al.
Publicado: (2023)

Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure
por: Chen, Qing, et al.
Publicado: (2019)

A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
por: Salpini, Romina, et al.
Publicado: (2020)

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023)

Paradoxical HBsAg and anti-HBs coexistence among Chronic HBV Infections: Causes and Consequences
por: Jiang, Xinyi, et al.
Publicado: (2021)

Reduced HBV cccDNA and HBsAg in HBV-associated hepatocellular carcinoma tissues
por: Tantiwetrueangdet, Anchalee, et al.
Publicado: (2018)

HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
por: Moini, Maryam, et al.
Publicado: (2022)

Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients
por: Liu, Xin, et al.
Publicado: (2023)

The role of HBsAg levels in the current management of chronic HBV infection
por: Höner zu Siederdissen, Christoph, et al.
Publicado: (2014)

Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV Infection
por: Cao, Jing, et al.
Publicado: (2020)

Correlation between HBsAg quantitative assay results and HBV DNA levels in chronic HBV
por: Ganji, Azita, et al.
Publicado: (2011)

Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection
por: Salpini, Romina, et al.
Publicado: (2020)

Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
por: Piermatteo, Lorenzo, et al.
Publicado: (2023)

Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs
por: Huang, Jing, et al.
Publicado: (2017)

HBV Genotyping in HBsAg-Positive Blood Donors from Southwestern Iran
por: Kohshour, Mojtaba Oraki, et al.
Publicado: (2010)

Correlation Between HBsAg Quantitation and HBV DNA in HBeAg-Negative HBV/D Patients
por: Teriaky, Anouar, et al.
Publicado: (2013)

The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing
por: Wang, Ying, et al.
Publicado: (2021)

HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
por: Gozlan, Yael, et al.
Publicado: (2022)

Pre-transplant donor HBV DNA+ and male recipient are independent risk factors for treatment failure in HBsAg+ donors to HBsAg- kidney transplant recipients
por: Wang, Xian-ding, et al.
Publicado: (2021)

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients
por: Cerva, Carlotta, et al.
Publicado: (2022)

The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment
por: Yin, Shengxia, et al.
Publicado: (2023)

Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes
por: Scheiblauer, H, et al.
Publicado: (2010)

Evolution of full-length genomes of HBV quasispecies in sera of patients with a coexistence of HBsAg and anti-HBs antibodies
por: Zhou, Tai-Cheng, et al.
Publicado: (2017)

Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups
por: Ning, Jing, et al.
Publicado: (2022)

Clinical Outcomes of Delayed Clearance of Serum HBsAg in Patients with Chronic HBV Infection
por: Nam, Soon Woo, et al.
Publicado: (2007)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
por: Kruse, Robert L., et al.
Publicado: (2017)

Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma
por: Pollicino, Teresa, et al.
Publicado: (2019)

Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients
por: Hsiao, Liang-Tsai, et al.
Publicado: (2016)

Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
por: Kim, Kwang Min, et al.
Publicado: (2011)

Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg
por: Wang, Tong, et al.
Publicado: (2019)

Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg
por: Wang, Tong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_btt2j946357oijemv68hjhra32